298 related articles for article (PubMed ID: 32226720)
1. Respiratory virus-induced heterologous immunity: Part of the problem or part of the solution?
Pusch E; Renz H; Skevaki C
Allergo J Int; 2018; 27(3):79-96. PubMed ID: 32226720
[TBL] [Abstract][Full Text] [Related]
2. Respiratory virus-induced heterologous immunity: Part of the problem or part of the solution?
Pusch E; Renz H; Skevaki C
Allergo J; 2018; 27(3):28-45. PubMed ID: 32300267
[TBL] [Abstract][Full Text] [Related]
3. Regional, age and respiratory-secretion-specific prevalence of respiratory viruses associated with asthma exacerbation: a literature review.
Zheng XY; Xu YJ; Guan WJ; Lin LF
Arch Virol; 2018 Apr; 163(4):845-853. PubMed ID: 29327237
[TBL] [Abstract][Full Text] [Related]
4. Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity.
Loos C; Atyeo C; Fischinger S; Burke J; Slein MD; Streeck H; Lauffenburger D; Ryan ET; Charles RC; Alter G
mSphere; 2020 Sep; 5(5):. PubMed ID: 32878931
[TBL] [Abstract][Full Text] [Related]
5. Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain-Specific Hemagglutinin-Based or Cross-Protective M2 Extracellular Domain-Based Vaccination.
Kim YJ; Kim KH; Ko EJ; Kim MC; Lee YN; Jung YJ; Lee YT; Kwon YM; Song JM; Kang SM
J Virol; 2018 Oct; 92(20):. PubMed ID: 30068650
[TBL] [Abstract][Full Text] [Related]
6. Rhinovirus Reduces the Severity of Subsequent Respiratory Viral Infections by Interferon-Dependent and -Independent Mechanisms.
Van Leuven JT; Gonzalez AJ; Ijezie EC; Wixom AQ; Clary JL; Naranjo MN; Ridenhour BJ; Miller CR; Miura TA
mSphere; 2021 Jun; 6(3):e0047921. PubMed ID: 34160242
[TBL] [Abstract][Full Text] [Related]
7. A polyvalent influenza A DNA vaccine induces heterologous immunity and protects pigs against pandemic A(H1N1)pdm09 virus infection.
Bragstad K; Vinner L; Hansen MS; Nielsen J; Fomsgaard A
Vaccine; 2013 Apr; 31(18):2281-8. PubMed ID: 23499598
[TBL] [Abstract][Full Text] [Related]
8. Virus-Induced T Cell-Mediated Heterologous Immunity and Vaccine Development.
Balz K; Trassl L; Härtel V; Nelson PP; Skevaki C
Front Immunol; 2020; 11():513. PubMed ID: 32296430
[TBL] [Abstract][Full Text] [Related]
9. Influenza-derived peptides cross-react with allergens and provide asthma protection.
Skevaki C; Hudemann C; Matrosovich M; Möbs C; Paul S; Wachtendorf A; Alashkar Alhamwe B; Potaczek DP; Hagner S; Gemsa D; Garn H; Sette A; Renz H
J Allergy Clin Immunol; 2018 Sep; 142(3):804-814. PubMed ID: 29132960
[TBL] [Abstract][Full Text] [Related]
10. The Potential of Neuraminidase as an Antigen for Nasal Vaccines To Increase Cross-Protection against Influenza Viruses.
Kawai A; Yamamoto Y; Nogimori T; Takeshita K; Yamamoto T; Yoshioka Y
J Virol; 2021 Sep; 95(20):e0118021. PubMed ID: 34379511
[TBL] [Abstract][Full Text] [Related]
11. Impairment of T cell immunity by the respiratory syncytial virus: targeting virulence mechanisms for therapy and prophylaxis.
González PA; Bueno SM; Riedel CA; Kalergis AM
Curr Med Chem; 2009; 16(34):4609-25. PubMed ID: 19903147
[TBL] [Abstract][Full Text] [Related]
12. The CD8 T Cell Response to Respiratory Virus Infections.
Schmidt ME; Varga SM
Front Immunol; 2018; 9():678. PubMed ID: 29686673
[TBL] [Abstract][Full Text] [Related]
13. Respiratory syncytial virus: the virus, the disease and the immune response.
Ogra PL
Paediatr Respir Rev; 2004; 5 Suppl A():S119-26. PubMed ID: 14980256
[TBL] [Abstract][Full Text] [Related]
14. CCR2 Regulates Vaccine-Induced Mucosal T-Cell Memory to Influenza A Virus.
Lee W; Kingstad-Bakke B; Kedl RM; Kawaoka Y; Suresh M
J Virol; 2021 Jul; 95(15):e0053021. PubMed ID: 33952647
[TBL] [Abstract][Full Text] [Related]
15. Innate and adaptive immune responses in respiratory virus infection: implications for the clinic.
Stambas J; Lu C; Tripp RA
Expert Rev Respir Med; 2020 Nov; 14(11):1141-1147. PubMed ID: 32762572
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Immune Responses to and Cross-Protective Efficacy of Eurasian H7 Avian Influenza Viruses.
Kwon HI; Kim YI; Park SJ; Song MS; Kim EH; Kim SM; Si YJ; Lee IW; Song BM; Lee YJ; Yun SJ; Kim WJ; Choi YK
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331080
[TBL] [Abstract][Full Text] [Related]
17. EGFR activation suppresses respiratory virus-induced IRF1-dependent CXCL10 production.
Kalinowski A; Ueki I; Min-Oo G; Ballon-Landa E; Knoff D; Galen B; Lanier LL; Nadel JA; Koff JL
Am J Physiol Lung Cell Mol Physiol; 2014 Jul; 307(2):L186-96. PubMed ID: 24838750
[TBL] [Abstract][Full Text] [Related]
18. Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats.
O'Konek JJ; Makidon PE; Landers JJ; Cao Z; Malinczak CA; Pannu J; Sun J; Bitko V; Ciotti S; Hamouda T; Wojcinski ZW; Lukacs NW; Fattom A; Baker JR
Hum Vaccin Immunother; 2015; 11(12):2904-12. PubMed ID: 26307915
[TBL] [Abstract][Full Text] [Related]
19. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
[TBL] [Abstract][Full Text] [Related]
20. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
